Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00567567 · OUTCOME

OS in Patients 12-18 Months, Stage 4, MYCN Nonamplified Tumor/Unfavorable Histopathology/Diploid DNA Content/Indeterminant Histology/Ploidy and Patients > 547 Days, Stage 3, MYCN Nonamplified Tumor AND Unfavorable Histopathology/Indeterminant Histology

Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma · Source last updated 2022-04-28

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
percent probability
Interval / dispersion
95% Confidence Interval
Time frame
Up to 3 years

What was measured

Kaplan-Meier curves of OS will be plotted, and the proportion of responders to induction therapy will be tabulated.

Groups in this outcome

Single HST (CEM)

Induction therapy + single myeloablative consolidation

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Single HST (CEM)27

Reported measurements

Source class 1
Values in percent probability · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Single HST (CEM)81.0Not reported65.196.9Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        65.1
        upper Limit
        96.9
        value
        81.0
denoms
  1. counts
    1. group Id
      OG000
      value
      27
    units
    Participants
description
Kaplan-Meier curves of OS will be plotted, and the proportion of responders to induction therapy will be tabulated.
dispersion Type
95% Confidence Interval
groups
  1. description
    Induction therapy + single myeloablative consolidation
    id
    OG000
    title
    Single HST (CEM)
param Type
NUMBER
reporting Status
POSTED
time Frame
Up to 3 years
title
OS in Patients 12-18 Months, Stage 4, MYCN Nonamplified Tumor/Unfavorable Histopathology/Diploid DNA Content/Indeterminant Histology/Ploidy and Patients > 547 Days, Stage 3, MYCN Nonamplified Tumor AND Unfavorable Histopathology/Indeterminant Histology
type
SECONDARY
unit Of Measure
percent probability

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice